AbbVie Inc. (NYSE:ABBV) and AstraZeneca PLC (NYSE:AZN) are both delivering earnings growth, but their latest results reveal different strengths. AbbVie is benefiting from rapid expansion in its immunology franchise, while AstraZeneca is generating considerable momentum from oncology and rare-disease treatments.
According to Yahoo Finance’s latest available valuation snapshots, AbbVie trades at 16.39 times forward earnings, compared with 14.62 times for AstraZeneca, suggesting investors are assigning a higher earnings multiple to AbbVie’s growth prospects.
When making an investment decision, investors must evaluate not just how quickly earnings are growing, but how sustainable that growth could be across each company’s portfolio. Let us help you with the comparison. But before we get into it, take a look at our ranking of the best healthcare stocks to buy according to hedge funds. Check out the complete list here for more insight into the sector.
Bull Case
AbbVie’s second-quarter 2026 results demonstrate the strength of its post-Humira growth strategy. Revenue increased 10.2% year over year to $16.99 billion, while adjusted earnings per share climbed 22.9% to $3.65. The company’s immunology franchise remains its primary growth driver. Skyrizi generated $5.51 billion in revenue, increasing 24.4% on a reported basis, while Rinvoq contributed $2.53 billion, up 24.5%.
Together, these medicines accounted for a significant chunk of AbbVie’s quarterly revenue, and their combined $8.03 billion contribution illustrates how successfully AbbVie has developed substantial revenue streams beyond Humira, whose quarterly sales declined 35.9%.
That commercial momentum provides tangible support for AbbVie’s earnings outlook. Its newer immunology medicines are already generating meaningful sales rather than representing growth opportunities dependent entirely on future regulatory approvals. Read more extensively about AbbVie’s bull and bear case here.
AstraZeneca PLC (NYSE:AZN), in contrast, presents a different growth story. Second-quarter revenue increased 6% on a reported basis to $15.38 billion, while core EPS rose 21% to $2.63 in reported currency terms.
Although its headline revenue growth was slower, AstraZeneca’s first-half therapeutic-area results reveal considerable underlying strength. Oncology revenue increased 15% at constant exchange rates to $14.1 billion, representing 46% of total revenue and taking its place as the largest therapy area. Rare Disease revenue also grew 11% to $4.9 billion.
Unlike AbbVie’s heavily immunology-driven growth, AstraZeneca has substantial contributions from oncology, rare disease, and other therapeutic areas. This provides investors with exposure to different sources of pharmaceutical demand, although diversification alone does not guarantee more durable earnings. We meticulously crafted a list of the 7 Best Pharma Stocks to Invest In Now. Access the complete list here.
Bear Case
Keep up with the healthcare sector through our insightful articles covering bull and bear cases. Along with BMY, read our recently published article on Danaher Has Barely Moved in a Year. Is its 25x Earnings Valuation Justified?
Anyway, AbbVie’s biggest strength also creates a concentration risk. With Skyrizi and Rinvoq contributing nearly half of quarterly revenue, sustaining their growth is increasingly important to the company’s overall performance. But other businesses are not growing at comparable rates. AbbVie’s oncology revenue declined 1.5% in the second quarter, while its aesthetics business increased just 0.3% on a reported basis.
These differences suggest that the company’s strong headline growth remains dependent on particular products rather than equally strong performance throughout its portfolio.
AstraZeneca’s diversification has its own limitations. First-half BioPharmaceuticals revenue declined 5% at constant exchange rates, including a 12% contraction in cardiovascular, renal, and metabolism revenue and a 26% decline in infectious-disease revenue. Consequently, strong oncology performance did not translate into equally impressive companywide growth.
AstraZeneca’s pipeline also requires careful interpretation. The company reported 183 pipeline projects, including 21 new molecular entities in late-stage development. While this demonstrates the scale of its research activities, pipeline breadth does not establish how many treatments will ultimately receive approval or become commercially successful.
What Does the Comparison Reveal?
AbbVie’s latest results demonstrate stronger companywide revenue growth and substantial commercial progress in replacing Humira. AstraZeneca PLC (NYSE:AZN) offers a broader therapeutic growth profile, supported by oncology and rare disease, but weaker performance elsewhere continues to weigh on overall expansion.
Both companies also reported strong adjusted or core earnings growth, although their respective non-GAAP accounting definitions are not identical. The valuation question therefore depends on how investors weigh AbbVie’s demonstrated immunology momentum against AstraZeneca’s broader opportunities and uneven segment performance.
The data helps identify the central trade-off between the two stocks, which is that AbbVie Inc. (NYSE:ABBV) has greater concentration in its strongest growth engines, while AstraZeneca’s wider portfolio has yet to deliver equally strong companywide sales growth.
While we acknowledge the risk and potential of AZN and ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
